Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Carl Zeiss Meditec AG    AFX   DE0005313704

CARL ZEISS MEDITEC AG

(AFX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Carl Zeiss Meditec AG: Revenue in second quarter of 2019/20 stagnating - Further impact on business development expected for second half 2019/20 - Currently no outlook for 2019/20 possible

share with twitter share with LinkedIn share with facebook
share via e-mail
04/02/2020 | 04:55am EDT

DGAP-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Half Year Results/Forecast
Carl Zeiss Meditec AG: Revenue in second quarter of 2019/20 stagnating - Further impact on business development expected for second half 2019/20 - Currently no outlook for 2019/20 possible

02-Apr-2020 / 10:50 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Revenue in second quarter of 2019/20 stagnating - Further impact on business development expected for second half 2019/20 - Currently no outlook for 2019/20 possible

Jena, April 2, 2020

Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of approx. EUR 715 million (previous year EUR 667.2 million) in the first six months of fiscal year 2019/20, based on preliminary data. Growth slowed significantly during the second quarter 2019/20, corresponding to revenue of approx. EUR 345 million (previous year EUR 343.5 million), about the prior year's level.

Further business results are not yet available at this point. The detailed results of the first six months of fiscal year 2019/20 will be published on May 11, 2020.

In light of the SARS-CoV-2 virus, which is currently spreading globally, and the associated negative effects on the global economy, management expects business development to be significantly impacted in the second half of 2019/20.

A reliable forecast of business development is currently not possible. For this reason, the executive management of Carl Zeiss Meditec will no longer abide by the forecast published in the annual report on Dec 6, 2019 for fiscal year 2019/20. As soon as providing a new forecast for the rest of the financial year becomes feasible, the company will publish it immediately.
 
 

Contact for investors and press
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
E-Mail: investors.meditec@zeiss.com


02-Apr-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena, Germany
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: investors.meditec@zeiss.com
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1013711

 
End of Announcement DGAP News Service

1013711  02-Apr-2020 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1013711&application_name=news&site_id=zonebourse

© EQS 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CARL ZEISS MEDITEC AG
07:32aCARL ZEISS MEDITEC AG : Independant Research remains a Sell rating
MD
05/20CARL ZEISS MEDITEC AG : DZ Bank gives a Neutral rating
MD
05/15CARL ZEISS MEDITEC AG : Release according to Article 40, Section 1 of the WpHG [..
EQ
05/12CARL ZEISS MEDITEC AG : Deutsche Bank reaffirms its Buy rating
MD
05/11CARL ZEISS MEDITEC AG : Sell rating from Kepler Chevreux
MD
05/11CARL ZEISS MEDITEC AG : Berenberg remains Neutral
MD
05/11CARL ZEISS MEDITEC : increases revenue in first six months of 2019/20
PU
05/11CARL ZEISS MEDITEC : increases revenue in first six months of 2019/20
EQ
05/06CARL ZEISS MEDITEC AG : half-yearly earnings release
05/04CARL ZEISS MEDITEC AG : Receives a Buy rating from Deutsche Bank
MD
More news
Financials (EUR)
Sales 2020 1 403 M
EBIT 2020 192 M
Net income 2020 140 M
Finance 2020 592 M
Yield 2020 0,62%
P/E ratio 2020 58,3x
P/E ratio 2021 39,4x
EV / Sales2020 5,14x
EV / Sales2021 4,41x
Capitalization 7 808 M
Chart CARL ZEISS MEDITEC AG
Duration : Period :
Carl Zeiss Meditec AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARL ZEISS MEDITEC AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 96,88 €
Last Close Price 87,30 €
Spread / Highest target 54,6%
Spread / Average Target 11,0%
Spread / Lowest Target -37,0%
EPS Revisions
Managers
NameTitle
Ludwin Monz President & Chief Executive Officer
Michael Kaschke Chairman-Supervisory Board
Justus Felix Wehmer Chief Financial Officer
Markus Guthoff Member-Supervisory Board
Cornelia Grandy Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
CARL ZEISS MEDITEC AG-23.22%8 926
THERMO FISHER SCIENTIFIC2.37%131 349
DANAHER CORPORATION3.11%112 119
INTUITIVE SURGICAL, INC.-4.80%65 433
ILLUMINA, INC.6.92%52 098
BOSTON SCIENTIFIC CORPORATION-19.97%51 566